Literature DB >> 17058066

Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.

L Majoros1, I Szegedi, G Kardos, C Erdész, J Kónya, C Kiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17058066     DOI： 10.1007/s10096-006-0200-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  6 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

2.  The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?

Authors:  Russell E Lewis; Nathan P Wiederhold
Journal:  Clin Infect Dis       Date:  2003-09-15       Impact factor: 9.079

3.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

5.  In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.

Authors:  Russell E Lewis; Nathan P Wiederhold; Randall A Prince; Dimitrios P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2005-12-30       Impact factor: 5.790

6.  Patterns of amphotericin B killing kinetics against seven Candida species.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
  6 in total
  3 in total

1.  Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Authors:  Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros
Journal:  Mycopathologia       Date:  2017-07-11       Impact factor: 2.574

2.  Development of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei.

Authors:  Merlijn H I van Haren; Theun de Groot; Bram Spruijtenburg; Kusum Jain; Anuradha Chowdhary; Jacques F Meis
Journal:  J Clin Microbiol       Date:  2021-11-17       Impact factor: 11.677

3.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.